Seattle Genetics says data backs Padcev combo for first-line bladder cancerSeattle Genetics and Astellas’ new drug for relapsed bladder cancer – Padcev – could move up the treatment Share XSeattle Genetics says data backs Padcev combo for first-line bladder cancerhttps://pharmaphorum.com/news/seattle-genetics-says-data-backs-padcev-combo-for-first-line-bladder-cancer/
Xtandi takes fight to prostate cancer rivals with survival dataPfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend Share XXtandi takes fight to prostate cancer rivals with survival datahttps://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/
Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapiesAstellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Share XAstellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapieshttps://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/
FDA backs Astellas/Seattle Genetics bladder cancer drugThe FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the Share XFDA backs Astellas/Seattle Genetics bladder cancer drughttps://pharmaphorum.com/news/fda-backs-astellas-seattle-genetics-bladder-cancer-drug/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
Patient-partnered drug discovery: vision or reality?pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Share XPatient-partnered drug discovery: vision or reality?https://deep-dive.pharmaphorum.com/magazine/patient-engagement/astellas-patient-partnered-drug-discovery-vision-or-reality/
Astellas buys gene therapy company for $3bnAstellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of Share XAstellas buys gene therapy company for $3bnhttps://pharmaphorum.com/news/astellas-acquires-gene-therapy-company-for-3bn/
AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
